Curious about the recent developments? Explore recent developments in the industry, research, and ImmunoShield Therapeutics itself.
Hydrogel Gel Injection Molding
Creating the vessel for therapeutic cells
Protection for the Immune System
From Mold to Gel
Provides a scalable platform
Biomaterials Marvel
Read “Hydrogel Injection Molding to Generate Complex Cell Encapsulation Geometries” for more information of the technology
Other Cell Therapies Coming to Market
Neurodegenerative Diseases
- Parkinson’s
- Alzheimer’s
- Huntington’s
Hormone Deficiencies
- Hemophilia
- Hypothyroidism
- Anemia
ImmunoShield’s platform technology is disease-agnostic, positioning us to capture value across multiple high-growth therapeutic areas
Go-to-Market Strategy
Strategic path from technology development to market-ready product through pharma partnerships
-
1-2 High-Risk Technology
Early stage, uncertain future
-
Current Stage3-4 De-risk Technology
Non-dilutive funding and seed investors to complete independent pre-clinical studies
-
5-6 Pharma Partnership
Investment and co-development for a cell therapy product with ImmunoShield's platform to complete IND-enabling studies
-
7-8 Safety & Efficacy Trials
Partner company takes over manufacturing and advancement of co-developed product after IND submission, starts clinical trials, potential acquisition
-
9 Market Ready Product
FDA approved product ready to scale
-
Near-Term (12-18 months)
- Complete independent pre-clinical studies
- Validate automated encapsulation platform
- Secure pharma partnership for co-development
-
Mid-Term (18-36 months)
- Complete IND-enabling studies with partner
- Submit IND for first indication
- Establish manufacturing partnerships
-
Long-Term (3+ years)
- Initiate Phase I/II clinical trials
- Explore acquisition opportunities
- Expand platform to additional indications
Strategic Partnership Model
Our go-to-market strategy leverages pharma partnerships to accelerate development, reduce capital requirements, and maximize value through strategic acquisition
- Lower Capital Need
Partner funds clinical development
- Faster to Market
Leverage partner infrastructure
- Higher Exit Value
Validated clinical data drives acquisition
Competitive Landscape
ImmunoShield's dual approach provides significant advantages over existing solutions
vs. Immunosuppressive Drugs
Current Standard of Care
- Severe side effects (infections, kidney damage, cancer risk)
- Excludes 80% of patient population
- Lifetime drug regimen required
- Significant ongoing costs
ImmunoShield Advantage
- No systemic immunosuppression needed
- Accessible to all patients
- One-time intervention
- Lower total cost of care
vs. Other Encapsulation Technologies
Existing Approaches
- Microencapsulation: difficult to retrieve, limited lifespan
- Traditional macrodevices: poor scalability
- Still vulnerable to indirect rejection
- Limited manufacturing throughput
ImmunoShield Advantage
- Retrievable spiral design
- Automated, scalable manufacturing
- Addresses both direct AND indirect rejection
- High-throughput production capability
vs. Gene Editing Approaches
Gene Editing Methods
- “Stealth cells” – complex manufacturing, uncertain longevity
- Higher regulatory hurdles
- Permanent genetic modifications
- Limited to specific cell types
ImmunoShield Advantage
- No genetic modification of therapeutic cells
- Clearer regulatory pathway
- Reversible intervention
- Platform applicable to any allogeneic cell type